focus -WSS

focus

author：explore 2025-10-01 12:54:53 - browse：2

Geoff Martha, CEO of Medtronic Courtesy Medtronic

As one of the largest and oldest medical device companies in the world, Medtronic has a foot in almost every clinical area.

The device maker with a market valuation of nearly $100 billion sells pacemakers, spinal cord stimulators, stents, monitors. Name a device, and they probably make it. The behemoth is ubiquitous in health care, but its size can make innovation sluggish. Medtronic has tried to become more streamlined in recent years — the company announced plans last year to spin off its patient monitoring and respiratory businesses, which Reuters recently reported, citing unnamed sources, may go to the Carlyle Group, a private equity firm.

Still, the device giant is immersed in many different specialties, including diabetes and high blood pressure, where the company has experienced some setbacks. Medtronic has sold old-school insulin pumps since the 1980s and therefore developed robust dosing algorithms, but has never successfully built a tubeless pump. The company plans to buy Korean patch pump maker EOFlow, but EOFlow is enmeshed in a patent battle with Insulet. A federal judge blocked EOFlow from selling its wearable patch pumps earlier this month.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： There's an unseen cost to disruptive road

WSS

To bolster infectious disease surveillance, genomics powerhouses team up

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

New report analyzes digital physical therapy solutions' effectiveness

Pumping milk in bathrooms at health conferences is common

California wildfire smoke linked to 52,000 early deaths, study says

What causes osteoarthritis? Researchers study link to brain protein

focus

focus

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Medicare drug price lawsuits could be good politics for Biden

Bright Health sells Medicare Advantage business to Molina

FDA sets aggressive timeline for overhauling inspection procedures

The high cost of giving birth even with insurance

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Walensky prepares to leave CDC — and Congress — behind

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Malaria cases in Florida and Texas: Here’s what you need to know

Cheap, fast test for Zika and dengue could cost just $1

Wikipedia

Cigna wins case to block Amy Bricker's move to CVS

The system is set up to fail children with medical complexity

'Essentially witchcraft:' A former naturopath takes on the field

NIH tests clinical research in primary care with $30 million program

Cigna wins case to block Amy Bricker's move to CVS

The inclusion problem at the heart of rehabilitation research

focus

focus

explore

explore